Patients with known brain metastases should be excluded from this clinical trial
24.0
Patients with known brain metastases should be excluded from this clinical trial
72.0
Patients with known brain metastases should be excluded from this clinical trial
42.0
Patients with known brain metastases should be excluded from this clinical trial; previously treated brain metastases, neurologically stable, and no ongoing or anticipated need for steroid therapy are eligible
12.0
Patients with known brain metastases should be excluded from early clinical trials
92.0
Patients with known leptomeningeal or brain metastases or spinal cord compression should be excluded from this clinical trial
250.0
Patients with known brain metastases should be excluded from this clinical trial
57.0
Patients with known brain metastases should be excluded from this clinical trial
36.0
Patients with known brain metastases should be excluded from this clinical trial
12.0
Participants with known brain metastases should be excluded from this clinical trial
42.0
Patients with known brain metastases should be excluded from this clinical trial
30.0
Patients with known brain metastases should be excluded from this clinical trial
46.0
Patients with known brain metastases should be excluded from this clinical trial
36.0
Patients with known brain metastases should be excluded from this clinical trial
45.0
Patients with known brain metastases are excluded
64.0
Patients with known brain metastases should be excluded from this clinical trial; a scan to confirm the absence of brain metastasis is not required
70.0
Patients with known brain metastases should be excluded from this clinical trial
150.0
Participants with known brain metastases should be excluded from this clinical trial
36.0
Patients with known brain metastases should be excluded from this clinical trial
24.0
Patients with known brain metastases should be excluded from this clinical trial except as those described below
72.0
Patients with known active or history of brain metastases should be excluded from this clinical trial
40.0
Patients with known brain metastases should be excluded from this clinical trial
22.0
